Studie

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Erkrankungsgruppe:

Solide Tumore, Leukämien und MDS

Organsystem:

Blut, Immunsystem, Lymphsystem

Stadium:

Rückfall, Therapierefraktär

Standort:

Essen

EudraCT:

2016-000227-71

Prüfplan-Code:

ITCC-059

Phase:

III

Prüfsubstanz:

Besponsa

Sponsor:

Erasmus Medical Center